Biotest AG Exceeds 2024 Financial Forecasts

Biotest AG has released preliminary business figures for the 2024 financial year, revealing revenue of €726.2 million, a 6.1% increase from the previous year. This surpasses the company's forecast for low single-digit growth. The revenue includes contributions from a collaboration with Grifols S.A.

Biotest reported a positive operating cash flow of €62.0 million, defying expectations of a negative mid-double-digit million range. The EBIT reached €94.5 million, aligning with the upper forecasted range of €80 million to €100 million.

The return on capital employed (ROCE) was 7.9%, within the expected 5-8% range, though lower than 2023’s 12.3%. These figures are based on IFRS standards and are preliminary and unaudited.

Biotest plans to publish its final 2024 financials and annual report on March 31, 2025.